BRAF and metastatic melanoma: Well ahead of projected view timelines, the FDA also approved Zelboraf (vemurafenib, Plexxikon / Diiachi-Sankyo / Roche) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, and co-approved the Cobas 4800 BRAF V600 Mutation Test, a diagnostic test developed by Roche to identify patients eligible for treatment.